Brenig Therapeutics Unveils AI-Driven Strategy for Brain-Penetrant Drugs

At the Keystone Symposia in Whistler, Canada, Dr. Alexei Pushechnikov will present new data on BT-409, a brain-penetrant NLRP3 inhibitor. The compound is the product of a Hybrid AI Platform developed alongside Expert Systems, Inc., which integrates physics-based structural biology with machine learning. This approach allows researchers to optimize potency, selectivity, and brain exposure in parallel rather than through the traditional, iterative process of tuning individual properties.

For years, drug developers have struggled to balance these competing requirements when targeting the central nervous system. Brenig’s methodology aims to resolve this by using molecular dynamics simulations to scan chemical space with higher precision. According to Dr. Pushechnikov, this engine enabled the discovery of an inhibitor that meets the specific biological demands of neuroinflammation, which is increasingly viewed as a key driver of disease progression in Parkinson’s and related disorders.

Beyond BT-409, the company is applying this platform to its clinical-stage LRRK2 inhibitor, BT-267. Megan McGill, CEO of Brenig Therapeutics, noted that the platform has already proven its utility by producing clinical assets with differentiated profiles. The presentation at the June 23 session marks a significant step in validating the company’s push toward creating best-in-class therapies for complex neurodegenerative and cardiometabolic diseases.